Short answer
Pulmonx Corp (LUNG) filed its Q1 2026 10-Q quarterly report on May 4, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $21M (down 8.7% year over year) with net income of −$14M.
Q1 2026 key financials · XBRL
- Revenue
- $21M
- −8.7% YoY
- Net income
- −$14M
- +5.5% YoY
- Operating margin
- -62.9%
- Gross margin
- 77.9%
- EPS (diluted)
- −$0.33
- +8.3% YoY
Source: XBRL data from the Pulmonx Corp (LUNG) Q1 2026 10-Q on SEC EDGAR. USD.
Pulmonx Corp Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $20.6M, down 8.7% YoY from $22.5M, primarily due to no China sales pending registration renewal
- Gross margin 77.9% vs 72.5% YoY, driven primarily by geographic mix
- U.S. revenue $13.3M vs $14.2M; international revenue $7.3M vs $8.3M
- Cash and equivalents $61.6M; $37.3M outstanding debt as of March 31, 2026
- $40.0M Perceptive Loan borrowed; CIBC Loan fully repaid in March 2026
Risk Factors
- Net losses $13.7 million in Q1 2026, with accumulated deficit $535.2 million as of March 31, 2026
- Zephyr Valve complications, including pneumothorax rates of 18–34% and four treatment-period deaths in LIBERATE
- Medicare coverage remains case-by-case, while some commercial payors still consider the solution medically unnecessary
- Revenue remains substantially dependent on Zephyr Valve and delivery-catheter sales
- Hospital contracting and European bidding processes may delay facility access and reduce sales
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Pulmonx Corp quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.